EISAI INC.

Lobbying for EISAI INC.

Filing Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$620,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Bills named in this filing 2

S 891
Bipartisan Health Care Act
HR 1
One Big Beautiful Bill Act

Lobbying activity 5

Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.

Taxation/Internal Revenue Code

Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.

Trade (domestic/foreign)

Issues related to supply chain and tariffs. Section 232 tariff investigation on branded pharmaceuticals.

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.